Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
How Will the Market Growth Rate of the Non-Viral Gene Delivery Technologies Market Impact Future Demand?
The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to the expansion of genetic research, rising prevalence of chronic genetic disorders, growing biotechnology and pharmaceutical research and development (R&D), the growth in genetic and molecular biology research, and increased government and institutional funding.
The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.06 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to growing demand for personalized medicine, increasing adoption in cancer and rare disease research, the rise of clustered regularly interspaced short palindromic repeats and gene editing technologies, rapid growth in mRNA-based therapeutics, and the growth of cell therapy and tissue engineering. Major trends in the forecast period include advancements in lipid nanoparticles and polymer-based vectors, development of deoxyribonucleic acid and ribonucleic acid therapeutics, integration with artificial intelligence and computational modeling, next-generation lipid nanoparticles (LNPs), and advancements in nanotechnology.
Claim your free report sample now:
What Are the Primary Growth Contributors in the Non-Viral Gene Delivery Technologies Market?
The increasing demand for personalized medicine is expected to propel the growth of the non-viral gene delivery technologies market going forward. Personalized medicine is a medical approach that customizes prevention, diagnosis, and treatment based on a person’s unique genetic makeup, lifestyle, and environmental influences. Increasing demand for personalized medicine is driven by advancements in genomic sequencing technologies, which allow for more accurate diagnosis, targeted therapies, and improved treatment outcomes tailored to individual patients. The growing focus on personalized medicine is driving demand for non-viral gene delivery technologies, as they offer safer and more adaptable methods to deliver therapeutic genes tailored to an individual’s genetic profile, without the risks associated with viral vectors. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the non-viral gene delivery technologies market.
What Are the Major Product/Service Segments in the Non-Viral Gene Delivery Technologies Market?
The non-viral gene delivery technologies market covered in this report is segmented
1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo
3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles
Which Trends Are Most Likely to Influence Non-Viral Gene Delivery Technologies Market Growth in the Next Decade?
Major companies operating in the non-viral gene delivery market are focusing on developing advanced solutions such as non-viral genetic medicine platforms to improve the safety and efficiency of gene therapies. A non-viral genetic medicine platform is a technology that introduces therapeutic genes or nucleic acids into cells without viruses, reducing immune reactions and safety concerns, enabling precise and controlled gene therapy delivery for multiple diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company that develops genetic medicines, launched immune-quiet DNA (iqDNA). This novel DNA is an optimized form of their closed-ended DNA (ceDNA) that evades innate immune detection, showing cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered via their lipid nanoparticle (LNP) system. Due to iqDNA's superior tolerability, Generation Bio is advancing this as the primary DNA cargo in all its programs, including its lead hemophilia A program.
Who Are the Prominent Players in theNon-Viral Gene Delivery Technologies Market?
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
Get the full non-viral gene delivery technologies market report here:
What Are the Opportunities and Challenges for Non-Viral Gene Delivery Technologies Market Across Regions?
North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment